Patents by Inventor Ali Salanti
Ali Salanti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11787844Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).Type: GrantFiled: February 8, 2013Date of Patent: October 17, 2023Assignee: VAR2 Pharmaceuticals APSInventors: Ali Salanti, Thor Grundtvig Theander, Mads Daugaard, Morten Nielsen, Madeleine Dahlback, Thomas Mandel Clausen
-
Publication number: 20230078675Abstract: The invention relates to a virus-like particle (VLP) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject. The VLP-based vaccine may be used for the prophylaxis and/or treatment of a disease including, but is not limited to, cancer, cardiovascular, infectious, chronic, neurological diseases/disorders, asthma, and/or immune-inflammatory diseases/disorders.Type: ApplicationFiled: October 18, 2022Publication date: March 16, 2023Inventors: Adam Frederik Sander Bertelsen, Ali Salanti, Thor Theander, Susan Thrane, Christoph Mikkel Janitzek, Mette Ørskov Agerbaek, Morten Agertoug Nielsen, Jan Tobias Gustafsson
-
Patent number: 11497800Abstract: The invention relates to a virus-like particle (VLP) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject. The VLP-based vaccine may be used for the prophylaxis and/or treatment of a disease including, but is not limited to, cancer, cardiovascular, infectious, chronic, neurological diseases/disorders, asthma, and/or immune-inflammatory diseases/disorders.Type: GrantFiled: November 22, 2019Date of Patent: November 15, 2022Assignee: University of CopenhagenInventors: Adam Frederik Sander Bertelsen, Ali Salanti, Thor Theander, Susan Thrane, Christoph Mikkel Janitzek, Mette Ørskov Agerbaek, Morten Agertoug Nielsen, Jan Tobias Gustafsson
-
Patent number: 11129882Abstract: The invention relates to a virus like particle (VLP) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject. The VLP based vaccine may be used for the prophylaxis and/or treatment of a disease including, but is not limited to, cancer, cardiovascular, infectious, asthma, and/or allergy diseases/disorders.Type: GrantFiled: October 28, 2016Date of Patent: September 28, 2021Assignee: University of CopenhagenInventors: Adam Frederik Sander Bertelsen, Ali Salanti, Thor Theander, Susan Thrane, Christoph Mikkel Janitzek, Mette Ørskov, Morten Agertoug Nielsen
-
Publication number: 20210278406Abstract: The present invention relates to functional binding fragments comprising the minimal CSA-binding fragments of VAR2CSA and their use in identification and isolation of circulating trophoblast and/or fetal cells suitable for non-invasive prenatal diagnostic testing. Thus, the present invention describes methods of identifying and isolating trophoblast and/or fetal cells in a biological sample such as a maternal blood, and utilizing this for prenatal diagnostics.Type: ApplicationFiled: July 12, 2019Publication date: September 9, 2021Inventors: Ali Salanti, Mads Daugaard
-
Publication number: 20200171138Abstract: The invention relates to a virus like particle (VLP) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject. The VLP based vaccine may be used for the prophylaxis and/or treatment of a disease including, but is not limited to, cancer, cardiovascular, infectious, asthma, and/or allergy diseases/disorders.Type: ApplicationFiled: October 28, 2016Publication date: June 4, 2020Inventors: Adam Frederik Sander Bertelsen, Ali Salanti, Thor Theander, Susan Thrane, Christoph Mikkel Janitzek, Mette Ørskov Agerbaek, Morten Agertoug Nielsen
-
Publication number: 20200115420Abstract: The invention relates to a virus-like particle (VLP) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject. The VLP-based vaccine may be used for the prophylaxis and/or treatment of a disease including, but is not limited to, cancer, cardiovascular, infectious, chronic, neurological diseases/disorders, asthma, and/or immune-inflammatory diseases/disorders.Type: ApplicationFiled: November 22, 2019Publication date: April 16, 2020Inventors: Adam Frederik Sander Bertelsen, Ali Salanti, Thor Theander, Susan Thrane, Christoph Mikkel Janitzek, Mette Ørskov Agerbaek, Morten Agertoug Nielsen, Jan Tobias Gustafsson
-
Patent number: 10526376Abstract: The invention relates to a virus-like particle (VLP) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject. The VLP-based vaccine may be used for the prophylaxis and/or treatment of a disease including, but is not limited to, cancer, cardiovascular, infectious, chronic, neurological diseases/disorders, asthma, and/or immune-inflammatory diseases/disorders.Type: GrantFiled: January 15, 2016Date of Patent: January 7, 2020Assignee: University of CopenhagenInventors: Adam Frederik Sander Bertelsen, Ali Salanti, Thor Theander, Susan Thrane, Christoph Mikkel Janitzek, Mette Ørskov Agerbaek, Morten Agertoug Nielsen, Jan Tobias Gustafsson
-
Publication number: 20190022206Abstract: The invention relates to a virus like particle (VLP) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject. The VLP based vaccine may be used for the prophylaxis and/or treatment of a disease including, but is not limited to, cancer, cardiovascular, infectious, asthma, and/or allergy diseases/disorders.Type: ApplicationFiled: October 30, 2016Publication date: January 24, 2019Inventors: Adam Frederik Sander Pedersen, Ali Salanti, Thor Theander, Susan Thrane, Christoph Mikkel Janitzek, Mette Ørskov Agerbaek, Morten Agertoug Nielsen
-
Publication number: 20180362591Abstract: The invention relates to a virus-like particle (VLP) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject. The VLP-based vaccine may be used for the prophylaxis and/or treatment of a disease including, but is not limited to, cancer, cardiovascular, infectious, chronic, neurological diseases/disorders, asthma, and/or immune-inflammatory diseases/disorders.Type: ApplicationFiled: January 15, 2016Publication date: December 20, 2018Inventors: Adam Frederik Sander Pedersen, Ali Salanti, Thor Theander, Susan Thrane, Christoph Mikkel Janitzek, Mette Ørskov Agerbæk, Morten Agertoug Nielsen, Jan Tobias Gustafsson
-
Patent number: 10086056Abstract: The invention relates to a virus-like particle (VLP) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject. The VLP-based vaccine may be used for the prophylaxis and/or treatment of a disease including, but is not limited to, cancer, cardiovascular, infectious, chronic, neurological diseases/disorders, asthma, and/or immune-inflammatory diseases/disorders.Type: GrantFiled: October 27, 2017Date of Patent: October 2, 2018Assignee: University of CopenhagenInventors: Adam Frederik Sander Pedersen, Ali Salanti, Thor Theander, Susan Thrane, Christoph Mikkel Janitzek, Mette Ørskov Agerbaek, Morten Agertoug Nielsen, Jan Tobias Gustafsson
-
Publication number: 20180125954Abstract: The invention relates to a virus-like particle (VLP) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject. The VLP-based vaccine may be used for the prophylaxis and/or treatment of a disease including, but is not limited to, cancer, cardiovascular, infectious, chronic, neurological diseases/disorders, asthma, and/or immune-inflammatory diseases/disorders.Type: ApplicationFiled: October 27, 2017Publication date: May 10, 2018Inventors: Adam Frederik Sander Pedersen, Ali Salanti, Thor Theander, Susan Thrane, Christoph Mikkel Janitzek, Mette Ørskov Agerbaek, Morten Agertoug Nielsen, Jan Tobias Gustafsson
-
Patent number: 9932375Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).Type: GrantFiled: October 5, 2016Date of Patent: April 3, 2018Assignee: VAR2 PHARMACEUTICALS APSInventors: Ali Salanti, Thor Grundtvig Theander, Mads Daugaard, Morten Nielsen, Madeleine Dahlback, Thomas Mandel Clausen
-
Patent number: 9926350Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).Type: GrantFiled: October 5, 2016Date of Patent: March 27, 2018Assignee: VAR2 PHARMACEUTICALS APSInventors: Ali Salanti, Thor Grundtvig Theander, Mads Daugaard, Morten Nielsen, Madeleine Dahlback, Thomas Mandel Clausen
-
Publication number: 20170081373Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).Type: ApplicationFiled: October 5, 2016Publication date: March 23, 2017Applicant: VAR2 PHARMACEUTICAL APSInventors: Ali Salanti, Thor Grundtvig Theander, Mads Daugaard, Morten Nielsen, Madeleine Dahlback, Thomas Mandel Clausen
-
Publication number: 20170016905Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).Type: ApplicationFiled: October 5, 2016Publication date: January 19, 2017Applicant: VAR2 PHARMACEUTICAL APSInventors: Ali Salanti, Thor Grundtvig Theander, Mads Daugaard, Morten Nielsen, Madeleine Dahlback, Thomas Mandel Clausen
-
Publication number: 20150004099Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).Type: ApplicationFiled: February 8, 2013Publication date: January 1, 2015Applicant: VAR2 PHARMACEUTICALS APSInventors: Ali Salanti, Thor Grundtvig Theander, Mads Daugaard, Morten Nielsen, Madeleine Dahlback, Thomas Mandel Clausen
-
Patent number: 8563008Abstract: The disclosure provides novel antigens involved in gestational malaria, and more particularly to polynucleotide and polypeptide sequences, conjugates, cloning vectors including the sequences for the preparation of immunogenic compositions and vaccines, antibodies, and to their for treating gestational malaria. Diagnostic methods and kits are described.Type: GrantFiled: April 17, 2008Date of Patent: October 22, 2013Assignees: Institut de Recherche pour le Development (IRD), Institut PasteurInventors: Philippe Lucien Deloron, Nicaise George Tuikue Ndam, Gwladys Irénée Bertin, Peter David, Emmanuel Bischoff, Caroline Stéphanie Proux, Jean-Yves Coppee, Ali Salanti, Thomas Lavstsen
-
Publication number: 20100255018Abstract: The present invention relates to novel antigens involved in gestational malaria, and more particularly to polynucleotide and polypeptide sequences, conjugates, cloning vectors including said sequences for the preparation of immunogenic compositions and vaccines, antibodies, and to the use thereof for treating gestational malaria. The invention also relates to diagnostic methods and kits.Type: ApplicationFiled: April 17, 2008Publication date: October 7, 2010Applicants: INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (IRD), INSTITUT PASTEURInventors: Philippe Lucien Deloron, Nicaise Georges Tuikue Ndam, Gwladys Irénée Bertin, Peter David, Emmanuel Bischoff, Caroline Stéphanie Proux, Jean-Yves Coppee Proux, Ali Salanti, Thomas Lavstsen
-
Patent number: 7745580Abstract: The present invention relates to nucleic acid molecules related to the var2csa gene family as well as amino acid sequences encoded by such nucleic acid molecules with respect to their role in mediating adhesion of infected red blood cells to chondroitin sulphate A (CSA) in the placenta which is characteristic for the pathogenesis of pregnancy associated malaria (PAM). Accordingly, The invention provides the use compounds that are related to VAR2CSA polypeptides var2csa nucleic acid molecules as medicaments, as well as it provides pharmaceutical compositions, in particular immunological compositions and vaccines, hereunder nucleotide-based vaccines comprising these compounds. In addition, the invention provides the use of the compounds mentioned for the manufacture of compositions, such as immunogenic compositions.Type: GrantFiled: December 30, 2003Date of Patent: June 29, 2010Assignee: Kobenhavns UniversitetInventors: Thor Grundtvig Theander, Ali Salanti, Lars Hviid, Trine Staalsø, Anja Tatiana Ramstedt Jensen, Thomas Lavstsen, Madelaine Dahlbäck